Introducing
The 1788 Platform
The future, in your hands.
The 1788 Platform is our most sophisticated and comprehensive surgical visualization solution for use in multiple specialties. The 1788 features vibrant images, improved ease of use and enhanced fluorescence imaging capabilities, designed for clearer visualization of perfusion and critical anatomy - when it matters most.
We developed the 1788 with built-in architecture to enable visualization of multiple optical imaging agents. Our goal is to help enhance and customize your OR experience, as you strive to provide the best patient care possible.1
Visualize your magnum opus.
Surgery, re-imagined.
OLED monitor
The 32” 4K OLED Surgical monitor can display more than one billion colors, enabling clearer observation of fine tissue types and structures at a variety of angles.
Fluorescence imaging, re-imagined
SPY Contrast, Overlay and ENV modes are integrated into the 1788 platform, offering clearer delineation of fluorescence signal for improved visualization of perfusion and critical anatomy.1
1788 camera
Greater image sensor sensitivity, higher contrast ratios via true black levels and a more versatile laser wavelength work simultaneously to produce a clear, vivid surgical image.
SPY-PHI
The SPY Portable Handheld Imager allows surgeons to visualize perfusion in open surgery.
PneumoClear all-inclusive insufflator
First all-inclusive system with integrated heating, humidification and smoke evacuation capabilities, taking your insufflation experience to the next level.2
Powerful and versatile CCU
Adapts to multiple specialties.
L12 light source
Improved light control with ‘safelight’ technology.
The 1788 Platform is now cleared to visualize CYTALUX.3,4
VPI
Connects to SPY-PHI to enable visualization in open surgery.
Connected OR cart
Optimized OR footprint and better manueverability.
The 1788 Platform
Now featuring:
Now featuring:
Tone mode
Designed to balance brightness and illuminate shadows across the field of view by enhancing posterior lighting without compromising foreground detail.
Full frame HDR
Seeing is believing! Now with high dynamic range (HDR), designed to provide more detail in shadows and highlights of the image.
Experience one billion colors
62.5x more colors for more authentic and vibrant anatomical imagery.
Fluorescence imaging, re-imagined
Experience clearer delineation of fluorescence signal designed for improved visualization of critical anatomy and perfusion.
1788 Platform:
Imaging modalities
Imaging modalities
White light
Vivid, vibrant white light image.
SPY overlay mode
Best in class 4K white light image with integrated fluorescence imaging.
SPY contrast mode
High-contrast fluorescence visualization in grayscale.
SPY ENV mode
4K fluorescence displayed in grayscale.
IRIS
Improved usability by enabling simultaneous visualization of fluorescence imaging and IRIS ureteral stents.
SPY CSI
Emits only green and short blue wavelengths to provide higher contrast of vascular structures on the mucosal surface.
SPY CSF
Provides a more detailed color map to evaluate a wider range of florescence intensities
Seeing is believing:
Introducing CYTALUX®
Introducing CYTALUX®
The 1788 Platform is cleared to visualize CYTALUX. CYTALUX is approved to help surgeons identify malignant and non-malignant lesions in adult patients with known or suspected lung cancer. It is an FDA approved targeted imaging agent designed to “highlight” lung cancer in the body, helping surgeons to see it in real-time as they operate.
CYTALUX, manufactured by On Target Laboratories, is administered intravenously 1-24 hours prior to surgery for lung cancer. The agent then circulates through the body, binding to cells and fluoresces using a specialized camera system. During a Phase 3 clinical trial6, CYTALUX enabled the detection of more cancer for removal7. The 1788 Platform is now cleared to visualize CYTALUX intraoperatively.
1788 Platform visualizing CYTALUX in lung cases*
As shown in overlay mode, contrast mode, respectively
1788 camera visualizing CYTALUX during lung surgery.
Experience everything in harmony.
A 40+ year legacy of excellence in surgical visualization.
All for you.
All for you.
Contact us
Thank you for your submission
Follow Stryker on Social Media!
References
Comparisons are to previous generation unless noted
- 1000904469
- PN 1000902616
- NDA 214907 for approved indications of use
- Sarkaria IS, Martin LW, Rice DC, Blackmon SH, Slade HB, Singhal S; ELUCIDATE Study Group. Pafolacianine for intraoperative molecular imaging of cancer in the lung: The ELUCIDATE trial. J Thorac Cardiovasc Surg. 2023 Mar 3:S0022-5223(23)00185-X. doi:10.1016/j.jtcvs.2023.02.025. Epub 2023 Mar 02. PMID: 37019717.
- CYTALUX Prescribing Information; https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214907s002lbl.pdf
- In a Phase 3, multi-center trial, imaging with Cytalux identified 10 occult synchronous malignant lesions in 8 subjects (8%, 95% CI, 3.5-15.2) undetected by white light.Clinicaltrials.gov ID: NCT04241315.
- Sarkaria IS, Martin LW, Rice DC, Blackmon SH, Slade HB, Singhal S; ELUCIDATE Study Group. Pafolacianine for intraoperative molecular imaging of cancer in the lung: The ELUCIDATE Trial. J Thorac Cadriovasc Surg. 2023 Dec;166(6):e468-es478. doi: 10.1016/j.jtcvs.2023.02.025. Epub 2023 Mar 3.
CYTALUX® is an FDA approved optical imaging agent indicated as an adjunct for intraoperative identification of:
- Malignant lesions in adult patients with ovarian cancer.
- Malignant and non-malignant pulmonary lesions in adult patients with known or suspected cancer in the lung.
See full prescribing information to learn more.
1000904514 Rev. A.